Prof. Dr. med. Claus-Henning Köhne

Leiter Onkologisches Zentrum
Klinikdirektor

Facharzt für Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie

Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF.
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.
Blood. 2011 Nov 16

Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; On behalf of the GBG/AGO/NOGGO study groups.
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Support Care Cancer. 2011 Nov;19(11):1789-95.

Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
J Cancer Res Clin Oncol. 2011 Sep 30

Peeters M, Cohn A, Köhne CH, Douillard JY.
Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma.
Clin Colorectal Cancer. 2011 Sep 16.

Blanke CD, Bot BM, Thomas DM, Bleyer A, Köhne CH, Seymour MT, de Gramont A, Goldberg RM, Sargent DJ.
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
J Clin Oncol. 2011 Jul 10;29(20):2781-6. Epub 2011 Jun 6.

Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status.
J Clin Oncol. 2011 May 20;29(15):2011-9.

Van Cutsem E, Bajetta E, Valle J, Köhne CH, Randolph Hecht J, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E.
Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma.
J Clin Oncol. 2011 May 20;29(15):2004-10.

Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Clin Ther. 2011 Apr;33(4):482-97.

Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF; German-Austrian AMLSG.
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.
Blood. 2011 Feb 17;117(7):2137-45.

Metzner B, Casper J, Hartung G, Rosien B, Hölzle E, Pelzer P, Köhne CH.
Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance.
Onkologie. 2011;34(4):208-9.

Sanne Lugthart, Stefan Gröschel, H. Berna Beverloo, Sabine Kayser, Peter J.M. Valk, Shama Lydia van Zelderen-Bhola, Gert J Ossenkoppele, Edo Vellenga, Eva van den Berg-de Ruiter, Urs Schanz, Gregor Verhoef, Augustin Ferrant, Claus-Henning Köhne, Michael Pfreundschuh, Heinz A. Horst, Elisabeth Koller, Marie von Lilienfeld-Toal, Martin Bentz, Arnold Ganser, Brigitte Schlegelberger, Martine Jotterand, Jürgen Krauter, Thomas Pabst, Matthias Theobald, Richard F Schlenk, Ruud Delwel, Konstanze Döhner, Bob Löwenberg, and Hartmut Döhner
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,500 cases of AML
J Clin Oncol. 2010 Aug 20;28(24):3890-8.

Eric Van Cutsem, Emilio Bajetta, Juan W Valle, Claus-Henning Köhne, Joel Randolph Hecht, Malcolm J Moore, Colin Germond, William Berg, Bee-Lian Chen, Tarja Jalava, David Lebwohl, Gerold Meinhardt, Dirk Laurent, and Edward Lin
A Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin/Fluorouracil/Leucovorin With or Without PTK787/ZK 222584 (Vatalanib) in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
J Clin Oncol. 2011 May 20;29(15):2004-10.

Primary analysis of a phase II, single arm study (20060314) combining panitumumab with FOLFIRI in the first line treatment of patients (Pts) with metastatic colorectal cancer (MCRC)
Köhne, CH; Mineur, L; Greil, R, et al.
Ann Oncol. 2010, 21: I51-I51

Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, SnellerV, Gallant G, Kanzler S.
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.
Br J Cancer. 2010 Feb 2;102(3):506-12. Epub 2010 Jan 12

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Lancet Oncol. 2010 Jan;11(1):38-47. Epub 2009 Nov 26.

Köhne CH, Lenz HJ.
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Oncologist. 2009 May;14(5):478-88

Schuette K, Folprecht G, Kretzschmar A, Link H, Köhne CH, Gruenwald V, Stahl M, Huebner G.
Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
Onkologie. 2009 Apr;32(4):162-6.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J Med. 2009 Apr 2;360(14):1408-17.

Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM.
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.
J Clin Oncol. 2009 Apr 20;27(12):1948-55.
Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410-1.

Kneba M, Schrader C, Köhne H.
[Antibody therapy in hematology and oncology--2].
Med Klin (Munich). 2009 Jan 15;104(1):28-49.

Kneba M, Schrader C, Köhne H.
[Antibody therapy in hematology and oncology - part 1].
Med Klin (Munich). 2008 Dec 15;103(12):843-59.

Huebner G, Link H, Köhne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A; German CUP Study Group.
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno-or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
Br J Cancer. 2009 Jan 13;100(1):44-9.

Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, Van Cutsem E, Gosney M, Köhne CH, Aapro M; SIOG.
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations.
Ann Oncol. 2009 Jan;20(1):5-16.

Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R;
Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
J Clin Oncol. 2008 Aug 1;26(22):3695-701.

Köhne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P.
Chemotherapy in elderly patients with colorectal cancer.
Oncologist. 2008 Apr;13(4):390-402.

Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH.
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
J Clin Oncol. 2008 Mar 20;26(9):1443-51

Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, Baselga J.
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Clin Cancer Res. 2008 Jan 1;14(1):215-23

Van Cutsem E, Van de Velde C, Roth A, Lordick F, Köhne CH, Cascinu S, Aapro M; European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Eur J Cancer. 2008 Jan;44(2):182-94.

Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E.
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Ann Oncol. 2008 May;19(5):920-6.

Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G; European Colorectal Metastases Treatment Group.
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
Eur J Cancer. 2007 Sep;43(14):2037-45.

Sorbye H, Köhne CH, Sargent DJ, Glimelius B.
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification.
Ann Oncol. 2007 Oct;18(10):1666-72.
Folprecht G, Köhne CH, Lutz MP.
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Cancer Treat Rev. 2007;134:425-40.

Punt CJ, Buyse M, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, Påhlman L, Sobrero A, Douillard JY.
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003

Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
J Clin Oncol. 2007 Jun 1;25(16):2212-7.

Fensterer H, Radlwimmer B, Sträter J, Buchholz M, Aust DE, Julié C, Radvanyi F, Nordlinger B, Belluco C, Van Cutsem E, Köhne CH, Kestler HA, Schwaenen C, Nessling M, Lutz MP, Lichter P, Gress TM; EORTC Gastrointestinal (GI) Group.
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks.
BMC Cancer. 2007 Apr 2;7:58.

Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stötzer O, Zeuzem S, Lordick F, Köhne CH, Kröning H, Steinmetz T, Depenbrock H, Heinemann V.
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.
Ann Oncol. 2007 Apr;18(4):745-51.

Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M.
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
Cancer Immunol Immun. 2006 Mar; 55(3): 268-276

Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P; European Colorectal Metastases Treatment Group.
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
Eur J Cancer. 2006 Sep;42(14):2212-21.

Sobrero A, Köhne CH.
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal.
Lancet Oncol. 2006 Jun;7(6):515-7

Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH.
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Ann Oncol. 2006 Mar;17(3):450-6.

Köhne CH, Folprecht G
On prejudice and facts and choices
Ann Oncol. 2006 Feb;17(2):185-7

Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schoffski P, Schmoll H, Van Cutsem E, Köhne CH.
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
Eur J Cancer. 2006 Jan;42(1):42-9.

Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH.
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Ann Oncol. 2006 Mar;17(3):450-6.

Aapro MS, Köhne CH, Cohen HJ, Extermann M.
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
Oncologist. 2005 Mar;10(3):198-204

Folprecht G, Köhne CH.
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Nat Clin Pract Oncol. 2005 Nov;2(11):578-87.

Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H, Köhne CH, Ehninger G, Schmitz M, Bornhauser M.
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
Cancer Immunol Immunother. 2005 Jul 21:1-9

Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP; European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: Randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group
J Clin Oncol. 2005;23 (36): 9250-9256

Köhne, CH
Importance of intensified chemotherapy and of new drugs for the adjuvant and palliative treatment of colorectal cancer
Chirurg Gastroenterol. 2005; 21(2): 145-150

Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M,Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, LangenbuchT, Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, NordlingerB; European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer GastrointestinalGroup Study 40986.
J Clin Oncol. 2005 Aug 1;23(22):4856-65.

Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH.
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
Ann Oncol. 2005 Aug;16(8):1311-9.

Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, Schuff-Werner P.
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
J Clin Pathol. 2005 May;58(5):553-5.

Köhne CH, Bruce C, Folprecht G, Audisio R.
Role of new agents in the treatment of colorectal cancer.
Surg Oncol. 2004 Aug-Nov;13(2-3):75-81.

G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, C.-H. Köhne
Efficacy of 5-FU based chemotherapy in elderly patients with metastatic colorectal cancer – a pooled analysis of clinical trials.
Ann Oncol. 2004 Sep;15(9):1330-8.

Meta-Analysis Group in Cancer
Modulation of 5-Fluororuracil by leucovorin in patients with advanced colorectal cancer. An updated meta-analysis based on 3300 patients.
J Clin Oncol. 2004 Sep 15;22(18):3766-75.

Schöffski P, Köhne CH.
Invited Commentary: Cetuximab – a safe and active monoclonal antibody for the treatment of patients with colorectal cancer.
Drugs. 2004;64(1):119-21.

Köhne CH, DuBois RN
COX-2 inhibition and colorectal cancer
Semin Oncol. 2004 Apr;31(2 Suppl 7):12-21.

Folprecht G, Köhne CH.
The role of new agents in the treatment of colorectal cancer.
Oncology. 2004;66(1):1-17.

Folprecht G, Köhne CH.
Prinzipien der postoperativen Therapie beim Rektumkarzinom
Chirurg. 2004 Jan;75(1):32-7.

E. Schleyer, S. Pursche, C. H. Köhne, U. Schuler, U. Renner, H. Gschaidmeiere, J. Freiberg-Richter, T. Leopold, A. Jenke, M. Bonin, T. Bergemann, P. le Coutre, M. Gruner, M. Bornhäuser, O. G. Ottmann and G. Ehninger
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):23-36.

JT Hartmann, K Oechsle, D Quietzsch, A Wein, RD Hofheinz, F Honecker, O Nehls, C-H Köhne, G Käfer, L Kanz and C Bokemeyer.
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
British Journal of Cancer (2003) 89, 2051 – 2056

Folprecht, G; Köhne, CH
Chemotherapeutic options of liver metastases
Chirurg Gastroenterol. 2003; 19 (4): 364-369

Honecker F, Köhne CH, Bokemeyer C.
Colorectal cancer in the elderly: is palliative chemotherapy of value?
Drugs & Aging. 2003;20(1):1-11.
Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC, Aapro MS.
EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer
Eur J Cancer. 2003 Nov;39(16):2264-72.

Ducreux M, Köhne CH, Schwartz GK, Vanhoefer U
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers
Ann Oncol. 2003;14 Suppl 2:ii17-23. Review.

Köhne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips
M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ.
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.
Br J Cancer. 2003 Sep 15;89(6):997-1001.

Köhne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ;
European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
J Clin Oncol. 2003 Oct 15;21(20):3721-8. Epub 2003 Sep 08.

Köhne CH, Hecker H.
Reply to Letter to the Editor "Laboratory variables to stratify metastatic colorectal cancer patients", by J. Watine (Ann Oncol 2003; 14: 1450-1451).
Ann Oncol. 2003 Sep;14(9):1451.

Kiani A, Köhne CH, Franz T, Passauer J, Haufe T, Gross P, Ehninger G and Schleyer E.
Pharmacokinetics of Gemcitabine in a Patient with End-Stage Renal Disease: Effective Clearance of its Main Metabolite by Standard Hemodialysis Treatment
Cancer Chemother Pharmacol. 2003 Mar;51(3):266-70. Epub 2003 Mar 4

Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr D, Köhne CH, Labianca R, Misky B, Nordlinger B, Roth A, Rougier P, Cancer Chemother Pharmacol Schmoll HJ.
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).
Eur J Cancer. 2002 Jul;38(11):1429-36.

Köhne CH, Höffken K, Vanhoefer U, Hossfeld K-D, Seeber S.
Therapie des metastasierten kolorektalen Karzinoms mit 5-FU/ Folinsäure und Irinotecan
Deutsches Ärzteblatt 99, Ausgabe 5 vom 01.02.02, Seite A-292
Steiner M, Schuff-Werner P, Freund M, Köhne CH.
Combined chemotherapy trials require combined pharmacogenetic approaches.
J Clin Oncol. 2002 Mar 1;20(5):1425-6.

Köhne CH, Cunningham D, Di Costanzo CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H.
Clinical determinants of survival in patients with 5-fluorouracil-based
treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Ann Oncol. 2002 Feb;13(2):308-17.

Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dorken B, Daniel PT.
The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines.
Oncogene. 2002 Jan 10;21(2):227-38.

Van Cutsem E, Douillard JY, Köhne CH.
Toxicity of irinotecan in patients with colorectal cancer.
N Engl J Med. 2001 Nov 1;345(18):1351-2.
Lorenz M, Mueller HH, Mattes E, Gassel HJ, Junginger T, Saeger HD, Schramm H, Staib-Sebler E, Vetter G, Heinrich S, Köhne CH.
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
Ann Oncol. 2001 Mar;12(3):321-5.

Köhne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M.
Chemotherapy in elderly patients with colorectal cancer.
Ann Oncol. 2001 Apr;12(4):435-42.
Thirion P, Piedbois P, Buyse M, O'Dwyer PJ, Cunningham D, Man A, Greco FA, Colucci G, Köhne CH, Di Constanzo F, Piga A, Palmeri S, Dufour P, Cassano A, Pajkos G, Pensel RA, Aykan NF, Marsh J, Seymour MT.
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
Br J Cancer. 2001 Mar 2;84(5):611-20.

Junghanss C, Leithauser M, Wilhelm S, Kleine HD, Knopp A, Decker S, Alscher A, Casper J, Köhne CH, Freund M.
High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize.
Ann Hematol. 2001 Feb;80(2):96-102.

Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Köhne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M.
Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
Eur J Surg Oncol. 2001 Feb;27(1):80-7.

Benter T, Teichgraber UK, Kluhs L, Papadopoulos S, Köhne CH, Felix R, Dorken B.
Anatomical variations in the internal jugular veins of cancer patients affecting central venous access. Anatomical variation of the internal jugular vein.
Ultraschall Med. 2001 Feb;22(1):23-6.

Kretzschmar A, Reichardt P, Hapke G, Hohenberger P, Benter T, Sturm I, Thuss-Patience PC, Daniel PT, Dörken B and Köhne CH.
Weekly 24h infusion of high dose 5-Fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.
Oncology. 2000 Jun;59(1):14-7.

Lorenz M, Heinrich S, Staib-Sebler E, Köhne CH, Wils J, Nordlinger B, Encke A.
Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant?
Eur J Cancer. 2000 May;36(8):957-65. Review.

Lorenz M, Müller HH, Staib-Sebler E, Vetter G, Gog C, Petrowsky H, Köhne CH.
Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma.
Langenbecks Arch Surg. 1999 Aug;384(4):328-38. Review.
Köhne CH, Midgley R, Seymour M, Kerr DJ.
Advanced colorectal cancer: which regimes should we recommend?
Ann Oncol. 1999 Aug;10(8):877-82.

Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT.
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
J Clin Oncol. 1999 May;17(5):1364-74.

Vanhöfer U, Harstrick A, Köhne CH, Achterrath W, Rustum YM, Seeber S and Wilke H.
Phase I study of a weekly schedule of Irinotecan, high dose leucovorin and infusional 5-Fluorouracil as first line chemotherapy in patients with advanced colorectal cancer.
J Clin Oncol 17:907-913, 1999

Schöffski P, Freund M, Wunder R, Petersen D, Köhne CH, Hecker H, Schubert U, Ganser A.
Randomized comparison of the feasibility and toxicity of amphotericin B in dextrose 5% or Intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin.
BMJ, 1998 317(7155):379-84.

Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Bade J, Strohmeyer G, Schubert U, Hecker H, Dörken B and Schmoll HJ.
Effective biomodulation by leucovorin of high dose infusional 5-Fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer.
J Clin Oncol 16: 418-426, 1998

Köhne CH, Lorenz M , Herrmann R
Colorectal cancer liver metastases - Local treatment for a systemic disease?
Ann Oncol 1998 Sep;9(9):967-71

Köhne CH, Kretzschmar A, Wils J
First-line chemotherapy for colorectal carcinoma: - we are making progress
Onkologie 1998; 21:280-289

Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretschmar A, Benter T, Dietz R and Dörken B.
Raltitrexed (Tomudex): An alternative drug for patients with 5-Fluorouracil associated cardiotoxicity.
Br J Cancer 77(6):973-977, 1998

Hartmann JT, Köhne CH, Schmoll HJ, Kanz L, Bokemeyer C.
Is continuous 24 hour-infusion of 5-Fluorouracil plus high dose folinic acid effective in patients with progressiveor recurrent colorectal cancer?
Oncology 1998 Jul-Aug;55(4):320-5

Köhne CH, Benter T.
Endoscopic follow-up care in colorectal cancer
Internist 1998 ;39(7):779-780
Lorenz M, Staib-Sebler E, Gog C, Petrowki H, Köhne CH, Enke A.
Pilotstudy on intensive weekly 24h intraarterial infusion with 5-FU and folinic acid for colorectal liver metastasis.
Oncology 55: 53-58, 1988

Köhne CH, Benter T.
Follow-up care in colorectal carcinoma – Utility of tumor markers
Internist 1998 ;38(4):363 -365

Harstrick A, Köhne CH, Hiddemann W, Preusser P, Strumberg D, Schmoll HJ, Seeber S and Wilke H.
Double modulation of 5-Fluorouracil, with methotrexate and low-dose n-(phosphone-acetyl)-L-aspartate (PALA) does not improve results in advanced pancreatic cancer.
Ann Oncol 8: 917-918, 1997

Köhne CH, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C , Dörken B and Schmoll HJ.
Modulation of 5-Fluorouracil with methotrexate and low dose N-(phosphonacetyl)-L-aspartat in patients with advanced colorectal cancer. Results of a phase II study.
Eur J Cancer 33, 1896-1899, 1997

.
Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne CH, Hartmann JT, Kanz L, and Schmoll HJ.
Treatment of brain metastases in patients with testicular Cancer.
J Clin Oncol. 1997 Apr;15(4):1449-54.

Köhne CH, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Käufer C, Fischer T, Ohl U, Urbanitz D, Balleisen L., Schmoll H-J.
Phase II evaluation of 5-Fluorouracil plus Folinic acid and alpha 2b interferon in metastatic colorectal cancer
Oncology 54:96-101 (1997).

Köhne CH, Wils J
Current controversies in cancer. Is intra-arterial Chemotherapy worthwhile in the tratment of patients with unresectable hepatic colorectal cancer metastases? Contra.
Eur J Cancer Vol. 32A, No13: 2195-2205 (1996).

Cohen AM, Kemeny NE, Köhne CH, Wils J, de Takats PG, Kerr DJ.
Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases?
Eur J Cancer. 1996 Dec;32A(13):2195-205.

Köhne CH, Daniel P
Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma [letter]
N-Engl-J-Med. Apr 11; 334(15): 990-1; discussion 991-2 (1996).

Cohen AM, Kemeny NE, Köhne CH, Wils J, de Takats PG, Kerr DJ.
Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases?
Eur J Cancer. 1996 Dec;32A(13):2195-205. Review.

Köhne CH, Wilke H, Hecker H, Schöffski P, Kaufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaassen U, et al.
Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Ann-Oncol. May; 6(5): 461-6 (1995)

Bokemeyer C, Kuczyk MA, Köhne CH, Haupt A, Schmoll HJ.
[Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis].
Med Klin (Munich). 1996 Nov 15;91(11):703-10. Review

Köhne CH, Hiddemann W, Schüller J, Weiss J, Lohrmann HP, Schmitz-Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, et al.
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
J-Clin-Oncol. 5: 1201-8 (1995)

Köhne CH, Hiddemann W, Schüller J, Weiss J, Lohrmann HP, Schmitz-Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, et al.
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
J Clin Oncol. 1995 May;13(5):1201-8.

Casper J, Casper S, Köhne-Wömpner CH, Bokemeyer C, Hecker H, Schmoll HJ
5-HT3-antagonist ondansetron for the treatment of chemotherapy induced nausea and vomiting in an outpatient population
Int J Cancer 4: 1283-1289 (1994)

Köhne-Wömpner CH, Schöffski P, Schmoll HJ.
Adjuvant therapy for colon adenocarcinoma - Current status of clinical investigation
Ann Oncol 5: 97-104 (1994)

Schöber C, Papageorgiou E, Harstrick A, Bokemeyer C, Mügge A, Stahl M, Wilke H, Poliwoda H, Hiddemann W, Köhne-Wömpner CH, et al.
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Cancer. 1993 Oct 1; 72(7): 2242-7

Harstrick A, Bokemeyer C, Schmoll HJ, Köhne-Wömpner CH, Knipp H, Schöffski P, Anagnou J, Wippermann B, Neumann S, Poliwoda H
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for meta¬static soft-tisse sarcoma in adults
Cancer Chemother Pharmacol 31 (2): 217-221 (1993)

Köhne-Wömpner CH, Schmoll HJ.
5-Fluorouracil modulation in colorectal carcinoma experience of German investigators.
Adv-Exp-Med-Biol.; 339: 99-107 (1993)

Bokemeyer C, Schmoll HJ, Harstrick A, Köhne-Wömpner CH, Poliwoda H
Treatment of adult osteosarcoma: single center results in 47 patients
Int J Oncol 3: 927-932 (1993)

Bokemeyer C, Harstrick A, Schmoll HJ, Köhne-Wömpner CH, Schöffski P, Poliwoda H.
Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas.
Ann-Oncol. (1992) 3: 487-8

Harstrick A, Bokemeyer C, Preusser P, Köhne-Wömpner CH, Meyer HJ, Stahl M, Schmoll HJ, Wilke H
Phase II study of single-agent etoposide in patients with metastatic squamous-cell-carcinoma of the eso¬phagus
Cancer Chemother Pharmacol 29: 321-322 (1992)

Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM.
Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials
Semin Oncol 19 (2): 105-125 (1992)

Wilke H, Stahl M, Schmoll HJ, Preusser P, Fink U, Meyer HJ, Achterrath W, Knipp H, Köhne-Wömpner CH, Harstrick A, Vanhöfer U, Seeber S.
Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer
Semin Oncol 19 (2): 215-219 (1992)

Schmoll HJ, Hiddemann W, Rustum Y, Köhne-Wömpner CH.
The emerging role for biomodulation of antineoplastic agents.
Semin-Oncol. 19 (2): 1-3 (1992)

Schöber C, Schmoll HJ, Köhne-Wömpner CH, Stahl M, Wilke H, Poliwoda H.
A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation
Semin Oncol 19 (2): 136-140 (1992)

Schmoll, HJ, Köhne-Wömpner CH, Hiddemann W, Knipp H, Bodenstein H, Schöffski P, Bokemeyer C, Lohrmann HP, Preiss J, Käufer C, Fischer JT, Balleisen L, Urbanitz D, Harstrick A, Hill H.
Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial
Semin Oncol 19 (2): 191-196 (1992)

Wilke H, Preusser P, Fink U, Stahl M, Meyer HJ, Achterrath W, Köhne-Wömpner CH, Schöber C, Harstrick A, Lenaz L, Meyer J, Schmoll HJ:
Pilot study with folinic acid, etoposide, 5-fluorouracil and cisplatin in advanced gastric and esophageal cancer
Tumordiag Ther 12:21-24 (1991)

Harstrick A, Schmoll HJ, Köhne-Wömpner CH, Bergmann L, Lammers U, Hohnloser J, Dölken G, Reichhardt P, Siegert W, Natt F, Räth U, Wilke H, Poliwoda H.
Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma
Ann Oncol 2: 197-202 (1991)

Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, Bergmann L, Lammers U, Freund M, Poliwoda H.
Cisplatin, etoposide ifosfamide (PEI) salvage therapy for refractory or relapsing germ cell carcinoma
J Clin Oncol 9: 1549-1555 (1991)

Stahl M, Wilke H, Preusser P, Fink U, Achterrath W, Schöber C, Köhne-Wömpner CH, Harstrick A, Meyer HJ, Lenaz L, Schmoll HJ.
Etoposide, leucovorin and 5-fluorouracil (ELF) in advanced gastric carcinoma - Final results of a phase-II-study in elderly patients or patients with cardiac risk
Onkologie 14: 314-318 (1991)

Harstrick A, Casper J, Köhne-Wömpner CH, Guba R, Wilke H, Poliwoda H, Schmoll HJ.
Comparative antitumor activity of four anthracycline derivates against heterotrans¬planted human testi¬cular carcinoma cell lines
Invest New Drugs 8: 19-24 (1990)

Schmoll HJ, Harstrick A, Köhne-Wömpner CH, Schöber C, Wilke H, Poliwoda H.
Modulation of cytotoxic drug activity by dipyridamole
Cancer Treat Rev 17: 57-65 (1990)

Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Meyer J, Siewert JR, Geerlings H, Köhne-Wömpner CH, Harstrick A, Schmoll HJ
New developments in the treatment of gastric carcinoma
Semin Oncol 17, 1: 61-70 (1990)

Harstrick A, Schmoll HJ, Wilke H, Schöber C, Stahl M, Köhne-Wömpner CH, Bokemeyer C, Dölken G, Burk K, Poliwoda H.
High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II study
Ann Oncol 1 (5): 375-376 (1990)